Catalog No.
KDD10401
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
M3, MORAb-003, MORAb-003-VCP-eribulin, MORAb-202, CAS: 896723-44-7
Background
Farletuzumab (MORAb-003) is a humanized α-FR-targeted monoclonal antibody derived from the murine antibody, LK26 (Teng, Xie, Teng, & Lee, 2012). In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts (Teng et al., 2012). Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6–18 months (Konner et al., 2010). Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer (Walters et al., 2013). The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer (PSOC, defined as a PFI of ≥ 6 months), in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study (ClinicalTrials.gov Identifier: NCT02631876) was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an α-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant α-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the α-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial (ClinicalTrials.gov Identifier: NCT02019524) for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial (NCT02764333) is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 (also called TPIV200), a vaccine consisting of proteins from α-FR mixed with GM-CSF, and durvalumab (MEDI4736).
Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models., PMID:40074693
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors., PMID:39853764
Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis., PMID:39677200
The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448
Integrating antibody drug conjugates in the management of gynecologic cancers., PMID:36878560
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer., PMID:36758420
Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer., PMID:34185411
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors., PMID:33926914
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models., PMID:33756060
Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer., PMID:32987283
Exploiting the folate receptor α in oncology., PMID:32152484
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast., PMID:30268765
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity., PMID:30262588
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding., PMID:30144039
Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys., PMID:29928988
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125., PMID:29041009
CA125 effects on humoral immunosuppression., PMID:29016358
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement., PMID:28881712
Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging., PMID:28826214
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer., PMID:28450240
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer., PMID:27797594
Profile of farletuzumab and its potential in the treatment of solid tumors., PMID:27022278
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse., PMID:27001568
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer., PMID:26644263
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors., PMID:26136852
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments., PMID:26063635
Folate receptor-α (FOLR1) expression and function in triple negative tumors., PMID:25816016
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives., PMID:25765457
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications., PMID:25564455
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer., PMID:25416196
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors., PMID:25380636
Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy., PMID:25363562
Major clinical research advances in gynecologic cancer in 2013., PMID:25045437
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review., PMID:25031539
Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging., PMID:24732155
International Association for the Study of Lung Cancer - 15th World Conference on Lung Cancer (October 27-31, 2013 - Sydney, Australia)., PMID:24524099
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer., PMID:24109193
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity., PMID:24025360
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer., PMID:23863359
Antibodies to watch in 2013: Mid-year update., PMID:23727858
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer., PMID:23474348
Farletuzumab in lung cancer., PMID:23357463
Which are the antibodies to watch in 2013?, PMID:23254906
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer., PMID:22955257
Clinical trials and future potential of targeted therapy for ovarian cancer., PMID:22926640
Clinical translation of folate receptor-targeted therapeutics., PMID:22663189
Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro., PMID:22644798
Role of farletuzumab in epithelial ovarian carcinoma., PMID:22591419
Molecular/genetic therapies in ovarian cancer: future opportunities and challenges., PMID:22343235
Monoclonal antibodies in gynecological cancer: a critical point of view., PMID:22235224
For research use only. Not for human or drug use.
